* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011
65% 25%
9
DNA P53, ATM G1 S G2 G1 M
1 2 3
Gozuacik D, Kimchi A. Oncogene. 23: 2891-906, 2004 Edinger AL, Thompson CB. Cancer Cell. 4: 422-4, 2003 JNK Shimizu S. et al. Oncogene. 29: 2070-82, 2010.
phamacokinetics pharmacodynamics A absorption/administration) D(distribution) M(metabolism),E(excretion, elimination),
1950, 1960 1970 1980 1990 2000
10 10 10 8 10 6 10 4 10 2 0 ( ).
- - < Kasibhatla et al. IJROBP 2007; 68: 1491-95 (%)
Recall phenomenon
RTOG8501 ct1-3, N0-1, M0 SCC (n=107) 16.9% AC (n= 23) 12.2% p 0.0001 RT alone 50.0Gy CRT 64Gy, 5FU/CDDP 27 0 Al-Sarraf M et al. J Clin Oncol 1997
Stage Stage,
Boost IMRT
Comparison of Heart and Coronary Artery Doses Associated With Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Distal Esophageal Cancer Kole et al., Int J Radiat Oncol Biol Phys 2012 IMRT 3D-RT IMRT
60Gy/30f 66Gy/33f), (1.5Gy/f, 2f/d, 45Gy/30f/ 54Gy/27f
CCRT) CCRT CCRT
2011 RCT 1) 2)
Chemoradiation Kaneyasu Y, et al. Int J Radiat Oncol Biol Phys 2009;; 75: 369-377.
i.a.
BR M :biological response modifier molecular-target therapy 98
BR M :biological response modifier molecular-target therapy 99
BR M :biological response modifier molecular-target therapy 100
DNA
Imatinib Gleevec Bcr-Abl, c-kit C M L, G IST Gefitinib Iressa E G F R-T K NSC L C E rlotinib Tarceva E G F R-T K NSC L C, PC Trastuzumab Herceptin Her2 Breast Ca, G C Sunitinib Sutent Multikinase R C C, G IST Sorafenib Nexavar Multikinase R C C, H C C Cetuximab E rbitax E G F R C R C Panitumumab Vectibix E G F R C R C Bevacizumab Avastin V E G F C R C, NSC L C Lapatinib Tyverb Her1/Her2 T K Breast Ca. Evelorimus Afinitor m-t O R R C C
Imatinib Gleevec Bcr-Abl, c-kit C M L, G IST Gefitinib Iressa E G F R-T K NSC L C -mab: E rlotinib Tarceva E G F R-T K NSC L C, PC Trastuzumab Herceptin Her2 Breast Ca, G C Sunitinib Sutent Multikinase R C C, G IST Sorafenib Nexavar Multikinase R C C, H C C Cetuximab E rbitax E G F R C R C Panitumumab Vectibix E G F R C R C Bevacizumab Avastin V E G F C R C, NSC L C Lapatinib Tyverb Her1/Her2 T K Breast Ca. Evelorimus Afinitor m-t O R R C C
Mg P 105
( CRP KL-6, SP-D CT
Bernier et al: Annals of Oncology 22: 2191 2200, 2011 Cetuximab RT alone RT+cetuximab
100mg, 1V 35,894 1 25 2 1 14 F O X F O X+ 100mg, 1V 72,768 100mg, 1V 50,291 1 360,000 720,000 / 30% 216,000 / 4 560,000-670,000 / 30% 168,000 / 1 200mg 5,426.2 1 4 21,848.8 655,464 / 7.9 10.7
Cetuximab : Gefinitib Eritinib,Lapatinib, Panitumumab,Nimotmumab,Bevacizumab Vandatanib,Celecoxib,KGF
- - Bonner et al. Lancet Oncology, 2009 Radiotherapy alone Radiotherapy + cetuximab RT alone Overall survival RT + cetuximab All grade grade 3/4 grade 4 All grade grade 3/4 grade 4 Skin reaction 94.3 21.2 1.4 98.2 35.1 1.9 Mucositis 93.9 51.9 4.2 93.3 55.8 6.3 Acne 9.9 1.4 0 83.7 16.8 0.5
over treatment
2009